×
Catalog Products » Recombinant Proteins » Cytokines » VEGF R1/Flt-1 Fc Chimera (aa27-328), Human

VEGF R1/Flt1, Human

Synonyms FLT1; Flt-1
Description Vascular endothelial growth factor receptor 1 (VEGF R1) , also known as FMS-like tyrosine kinase (Flt1), is a receptor tyrosine kinase which plays a critical role in angiogenesis. Human VEGF R1 contains a signal peptide (aa 1-22), an extracellular domain (ECD aa 27-758) with seven Ig-like repeats, a trans-membrane domain (aa 759-780) and a cytoplasmic region (aa 781-1338) with a tyrosine kinase domain and several autocatalytic phosphotyrosine sites. VEGFR-1 and VEGFR-2 are closely related receptor tyrosine kinases and have both common and specific ligands. VEGFR-1 is a kinase-impaired RTK whereas VEGFR-2 is a highly active kinase. Vascular endothelial growth factors (VEGFs) are crucial regulators of vascular development during embryogenesis (vasculogenesis) as well as blood-vessel formation (angiogenesis) in the adult. In mammals, five VEGF ligands, which occur in several different splice variants and processed forms, have been identified so far. These ligands bind in an overlapping pattern to VEGF receptor-1, -2 and -3 (VEGFR1-3), as well as to co-receptors (here defined as VEGF-binding molecules that lack established VEGF-induced catalytic function), such as heparin sulphate proteoglycans (HSPGs) and neuropilins.
Recombinant Human VEGF R1 produced in CHO cells is a polypeptide chain containing 535 amino acids. rhVEGF R1 has a molecular mass of 80 kDa analyzed by reducing SDS-PAGE and is obtained by chromatographic techniques at GenScript.
Accession No P17948
Source CHO
Specific Activity Measured by its ability to inhibit the VEGF dependent proliferation of HUVEC (human umbilical vein endothelial cells).The ED50 for this effect is < 30 ng/mL in the presence of 2.5 ng/mL rhVEGF165 (Catalog: Z02689-10).
Sequence
SKLKDPELSL KGTQHIMQAG QTLHLQCRGE AAHKWSLPEM
VSKESERLSI TKSACGRNGK QFCSTLTLNT AQANHTGFYS CKYLAVPTSK
KKETESAIYI FISDTGRPFV EMYSEIPEII HMTEGRELVI PCRVTSPNIT
VTLKKFPLDT LIPDGKRIIW DSRKGFIISN ATYKEIGLLT CEATVNGHLY
KTNYLTHRQT NTIIDVQIST PRPVKLLRGH TLVLNCTATT
PLNTRVQMTW SYPDEKNKRA SVRRRIDQSN SHANIFYSVL TIDKMQNKDK
GLYTCRVRSG PSFKSVNTSV HIIEGRMDDK THTCPPCPAP ELLGGPSVFL
FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR
EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ
PREPQVYTLP PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE
SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL
HNHYTQKSLS LSPGK

Measured Molecular Weight 80 kDa, observed by reducing SDS-PAGE.
Purity > 95% as analyzed by SDS-PAGE.
Formulation Lyophilized after extensive dialysis against PBS.
Reconstitution Reconstituted in ddH2O or PBS at 100 μg/ml.
Endotoxin Level < 0.2 EU/μg, determined by LAL method.
Storage Lyophilized recombinant Human VEGF R1/Flt-1 remains stable up to 6 months at -80°C from date of receipt. Upon reconstitution, Human VEGF R1/Flt-1 should be stable up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.
Note For research use only




Notice there is no results found, you can visit "Citations Database" for other results.







For more documents, please visit "Technical Support".

Cat. No. Z03365
Size
Price
50 ug $159.00
*
*
*
*